Search For "drug controller general of india dcgi"
Zydus gets Mexican regulator nod to conduct clinical trials with Pegylated
Updated : 5 years, 11 months ago IST
Ahmedabad (Gujarat) [India], July 17 (ANI): Pharmaceutical major Zydus said on Friday it has got approval from Mexico's Federal Commission for the Protection against Sanitary Risk (COFEPRIS) to conduct clinical trials with its biological therapy 'Pegylated Interferon alpha-2b' for the treatm
Read More
DCGI gives market approval for Pneumococcal Polysaccharide Conjugate Vacci
Updated : 5 years, 11 months ago IST
New Delhi [India], July 15 (ANI): The Drug Controller General of India (DCGI) has given approval to the first fully indigenously developed Pneumococcal Polysaccharide Conjugate Vaccine.
Read More
DCGI approves Itolizumab injection for restricted emergency use on COVID-1
Updated : 5 years, 12 months ago IST
New Delhi [India], July 11 (ANI): The Drug Controller General of India (DCGI) granted its permission to Itolizumab injection for the restricted emergency use on COVID-19 patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) due to virus.
Read More
Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per via
Updated : 6 years ago IST
Bengaluru (Karnataka) [India], July 7 (ANI): Global pharmaceutical major Mylan has got approval for its remdesivir from the Drug Controller General of India (DCGI) and will launch a generic version of Gilead Sciences' COVID-19 anti-viral in the country at Rs 4,800 for 100 mg/vial.
Read More
DCGI permits human clinical trials for COVID-19 vaccine of Zydus Cadila
Updated : 6 years ago IST
New Delhi [India], July 3 (ANI): The Drug Controller General of India (DCGI) on Thursday granted permission to pharma giant Zydus Cadila to conduct phase I and phase II human clinical trials for COVID -19 vaccine, a top government official told ANI.
Read More
DCGI gives nod to Mylan labs to manufacture remdesivir for 'restricted eme
Updated : 6 years ago IST
New Delhi [India], July 2 (ANI): The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for 'restricted emergency use' on hospitalised COVID-19 patients, a senior government official said on Thursday.
Read More
DCGI gives nod to Bharat Biotech to conduct phase I & II Human clinica
Updated : 6 years ago IST
New Delhi [India], June 30 (ANI): The Drug Controller General of India (DCGI) has granted permission to Bharat Biotech International Limited (BBIL) to conduct Phase I and II Human clinical trials to develop an indigenous vaccine for COVID-19 -- in the name COVAXIN.
Read More
Anti-viral drug favipiravir gets DGCI nod for 'restricted emergency use' i
Updated : 6 years ago IST
New Delhi [India], June 19 (ANI): The Drug Controller General of India (DCGI) has granted permission to anti-viral drug favipiravir for "restricted emergency use" in mild to moderate cases of COVID-19, a senior government official confirmed to ANI.
Read More
COVID-19: Pharma giants seek DCGI's approval to manufacture, sell Remdesiv
Updated : 6 years, 1 month ago IST
New Delhi [India], June 4 (ANI): Two domestic pharmaceutical firms--Mylan and Jubilant Life Sciences have approached the country's top drug regulator--Drug Controller General of India (DCGI) to seek its approval to manufacture and sell anti-viral drug 'Remdesivir' in India to combat COVID-19
Read More
Zydus Cadila approaches DCGI to use hepatitis drug for COVID-19 clinical t
Updated : 6 years, 2 months ago IST
New Delhi [India], May 5 (ANI): The country's top drug regulator, Drug Controller General of India (DCGI), has received an application from Zydus Cadila, the leading global pharmaceutical company in India, to conduct clinical trial using antiviral drug 'Pegylated Interferon Alpha-2b' in adul
Read More
Glenmark to conduct clinical trials on Favipiravir anti-viral tablets for
Updated : 6 years, 2 months ago IST
Mumbai (Maharashtra) [India], April 30 (ANI): Glenmark Pharmaceuticals said on Thursday it has received approval from the Drug Controller General of India (DCGI) to conduct clinical trials on Favipiravir anti-viral tablets on COVID-19 patients.
Read More
DCGI permits import of drug with residual shelf life less than 60 pc
Updated : 6 years, 2 months ago IST
New Delhi [India], April 18 (ANI): In view of the COVID-19 pandemic, the country's top drug controller has granted permission for the import of drugs with residual shelf life less than 60 per cent under special conditions. This will be effective for a period of three months or till further o
Read More